Department of Biotechnology, School of Bioengineering, SRM University, Chennai, Tamil Nadu, India.
Chem Biol Drug Des. 2012 May;79(5):749-59. doi: 10.1111/j.1747-0285.2012.01336.x. Epub 2012 Mar 7.
The prevalence of allergic disease is increasing dramatically in the developed world. Studies of allergic diseases have clearly demonstrated that histamine plays an important role in the pathogenesis of the early-phase allergic response. Histamine effects are mediated by H1, H2, H3, and H4 receptors. The presence of the histamine H4 receptors on leukocytes and mast cells suggests that the new histamine receptor H4 plays an important role in the modulation of the immune system. Thus, histamine H4 receptor is an attractive target for anti-allergic therapy. In our present study, we have generated a histamine H4 receptor model using I-TASSER based on human B2-adrenergic G-protein-coupled receptor. Structurally similar compounds of the three known antagonists JNJ777120, thioperamide, and Vuf6002 were retrieved from PubChem, and database was prepared. Virtual screening of those databases was performed, and six compounds with high docking score were identified. Also the binding mode revealed that all the six compounds had interaction with Asp94 of the receptor. Our results serve as a starting point in the development of novel lead compounds in anti-allergic therapy.
在发达国家,过敏性疾病的患病率正在急剧上升。过敏性疾病的研究清楚地表明,组胺在早期过敏反应的发病机制中起着重要作用。组胺的作用是通过 H1、H2、H3 和 H4 受体介导的。白细胞和肥大细胞存在组胺 H4 受体表明新的组胺受体 H4 在免疫系统的调节中起着重要作用。因此,组胺 H4 受体是抗过敏治疗的一个有吸引力的靶点。在我们目前的研究中,我们使用基于人 B2-肾上腺素能 G 蛋白偶联受体的 I-TASSER 生成了组胺 H4 受体模型。从 PubChem 中检索到三种已知拮抗剂 JNJ777120、噻哌酰胺和 Vuf6002 的结构相似化合物,并准备了数据库。对这些数据库进行了虚拟筛选,鉴定出了 6 种具有高对接评分的化合物。结合模式还表明,所有 6 种化合物都与受体的 Asp94 相互作用。我们的研究结果为开发新型抗过敏治疗的先导化合物提供了一个起点。